168 related articles for article (PubMed ID: 17237266)
1. Epidermal growth factor receptor inhibition sensitizes renal cell carcinoma cells to the cytotoxic effects of bortezomib.
An J; Rettig MB
Mol Cancer Ther; 2007 Jan; 6(1):61-9. PubMed ID: 17237266
[TBL] [Abstract][Full Text] [Related]
2. Maximal apoptosis of renal cell carcinoma by the proteasome inhibitor bortezomib is nuclear factor-kappaB dependent.
An J; Sun Y; Fisher M; Rettig MB
Mol Cancer Ther; 2004 Jun; 3(6):727-36. PubMed ID: 15210859
[TBL] [Abstract][Full Text] [Related]
3. Synergistic anti-proliferative and pro-apoptotic activity of combined therapy with bortezomib, a proteasome inhibitor, with anti-epidermal growth factor receptor (EGFR) drugs in human cancer cells.
Cascone T; Morelli MP; Morgillo F; Kim WY; Rodolico G; Pepe S; Tortora G; Berrino L; Lee HY; Heymach JV; Ciardiello F
J Cell Physiol; 2008 Sep; 216(3):698-707. PubMed ID: 18381602
[TBL] [Abstract][Full Text] [Related]
4. Lapatinib-induced NF-kappaB activation sensitizes triple-negative breast cancer cells to proteasome inhibitors.
Chen YJ; Yeh MH; Yu MC; Wei YL; Chen WS; Chen JY; Shih CY; Tu CY; Chen CH; Hsia TC; Chien PH; Liu SH; Yu YL; Huang WC
Breast Cancer Res; 2013 Nov; 15(6):R108. PubMed ID: 24216290
[TBL] [Abstract][Full Text] [Related]
5. VHL expression in renal cell carcinoma sensitizes to bortezomib (PS-341) through an NF-kappaB-dependent mechanism.
An J; Fisher M; Rettig MB
Oncogene; 2005 Feb; 24(9):1563-70. PubMed ID: 15608669
[TBL] [Abstract][Full Text] [Related]
6. NF-κB inhibition by bortezomib permits IFN-γ-activated RIP1 kinase-dependent necrosis in renal cell carcinoma.
Thapa RJ; Chen P; Cheung M; Nogusa S; Pei J; Peri S; Testa JR; Balachandran S
Mol Cancer Ther; 2013 Aug; 12(8):1568-78. PubMed ID: 23657944
[TBL] [Abstract][Full Text] [Related]
7. Nuclear factor-kappaB p65 small interfering RNA or proteasome inhibitor bortezomib sensitizes head and neck squamous cell carcinomas to classic histone deacetylase inhibitors and novel histone deacetylase inhibitor PXD101.
Duan J; Friedman J; Nottingham L; Chen Z; Ara G; Van Waes C
Mol Cancer Ther; 2007 Jan; 6(1):37-50. PubMed ID: 17237265
[TBL] [Abstract][Full Text] [Related]
8. MKP1 repression is required for the chemosensitizing effects of NF-kappaB and PI3K inhibitors to cisplatin in non-small cell lung cancer.
Cortes-Sempere M; Chattopadhyay S; Rovira A; Rodriguez-Fanjul V; Belda-Iniesta C; Tapia M; Cejas P; Machado-Pinilla R; Manguan-García C; Sánchez-Pérez I; Nistal M; Moratilla C; de Castro-Carpeño J; Gonzalez-Barón M; Albanell J; Perona R
Cancer Lett; 2009 Dec; 286(2):206-16. PubMed ID: 19553005
[TBL] [Abstract][Full Text] [Related]
9. [Effects of the phosphoinostitide-3'-kinase delta inhibitor, CAL-101, in combination with Bortezomib on mantle lymophma cells and exploration of its related mechanism].
Qu F; Xia B; Li X; Guo S; Zhang L; Tian C; Yu Y; Zhang Y
Zhonghua Zhong Liu Za Zhi; 2015 Jun; 37(6):412-7. PubMed ID: 26463142
[TBL] [Abstract][Full Text] [Related]
10. Synergistic activity of bortezomib and HDACi in preclinical models of B-cell precursor acute lymphoblastic leukemia via modulation of p53, PI3K/AKT, and NF-κB.
Bastian L; Hof J; Pfau M; Fichtner I; Eckert C; Henze G; Prada J; von Stackelberg A; Seeger K; Shalapour S
Clin Cancer Res; 2013 Mar; 19(6):1445-57. PubMed ID: 23357978
[TBL] [Abstract][Full Text] [Related]
11. Bortezomib inhibits nuclear factor-kappaB dependent survival and has potent in vivo activity in mesothelioma.
Sartore-Bianchi A; Gasparri F; Galvani A; Nici L; Darnowski JW; Barbone D; Fennell DA; Gaudino G; Porta C; Mutti L
Clin Cancer Res; 2007 Oct; 13(19):5942-51. PubMed ID: 17908991
[TBL] [Abstract][Full Text] [Related]
12. Differential cellular and molecular effects of bortezomib, a proteasome inhibitor, in human breast cancer cells.
Codony-Servat J; Tapia MA; Bosch M; Oliva C; Domingo-Domenech J; Mellado B; Rolfe M; Ross JS; Gascon P; Rovira A; Albanell J
Mol Cancer Ther; 2006 Mar; 5(3):665-75. PubMed ID: 16546981
[TBL] [Abstract][Full Text] [Related]
13. Antitumor effects of the proteasome inhibitor bortezomib in medullary and anaplastic thyroid carcinoma cells in vitro.
Mitsiades CS; McMillin D; Kotoula V; Poulaki V; McMullan C; Negri J; Fanourakis G; Tseleni-Balafouta S; Ain KB; Mitsiades N
J Clin Endocrinol Metab; 2006 Oct; 91(10):4013-21. PubMed ID: 16849420
[TBL] [Abstract][Full Text] [Related]
14. N-(4-hydroxyphenyl)retinamide inhibits invasion, suppresses osteoclastogenesis, and potentiates apoptosis through down-regulation of I(kappa)B(alpha) kinase and nuclear factor-kappaB-regulated gene products.
Shishodia S; Gutierrez AM; Lotan R; Aggarwal BB
Cancer Res; 2005 Oct; 65(20):9555-65. PubMed ID: 16230421
[TBL] [Abstract][Full Text] [Related]
15. Phase I study of bortezomib and cetuximab in patients with solid tumours expressing epidermal growth factor receptor.
Dudek AZ; Lesniewski-Kmak K; Shehadeh NJ; Pandey ON; Franklin M; Kratzke RA; Greeno EW; Kumar P
Br J Cancer; 2009 May; 100(9):1379-84. PubMed ID: 19401697
[TBL] [Abstract][Full Text] [Related]
16. Bortezomib sensitizes human renal cell carcinomas to TRAIL apoptosis through increased activation of caspase-8 in the death-inducing signaling complex.
Brooks AD; Jacobsen KM; Li W; Shanker A; Sayers TJ
Mol Cancer Res; 2010 May; 8(5):729-38. PubMed ID: 20442297
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of bortezomib-resistant constitutive NF-kappaB activity in mantle cell lymphoma.
Yang DT; Young KH; Kahl BS; Markovina S; Miyamoto S
Mol Cancer; 2008 May; 7():40. PubMed ID: 18489772
[TBL] [Abstract][Full Text] [Related]
18. Differential bortezomib sensitivity in head and neck cancer lines corresponds to proteasome, nuclear factor-kappaB and activator protein-1 related mechanisms.
Chen Z; Ricker JL; Malhotra PS; Nottingham L; Bagain L; Lee TL; Yeh NT; Van Waes C
Mol Cancer Ther; 2008 Jul; 7(7):1949-60. PubMed ID: 18645005
[TBL] [Abstract][Full Text] [Related]
19. NF-kappaB inhibition through proteasome inhibition or IKKbeta blockade increases the susceptibility of melanoma cells to cytostatic treatment through distinct pathways.
Amschler K; Schön MP; Pletz N; Wallbrecht K; Erpenbeck L; Schön M
J Invest Dermatol; 2010 Apr; 130(4):1073-86. PubMed ID: 19940859
[TBL] [Abstract][Full Text] [Related]
20. Antitumor effects of bortezomib (PS-341) on primary effusion lymphomas.
An J; Sun Y; Fisher M; Rettig MB
Leukemia; 2004 Oct; 18(10):1699-704. PubMed ID: 15343345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
